Holen Sie sich die Stockscreener-App
33.97
0.59%
-0.20
Handel nachbörslich:
33.95
-0.02
-0.06%
Schlusskurs vom Vortag:
$34.17
Offen:
$34.17
24-Stunden-Volumen:
213.20K
Relative Volume:
0.50
Marktkapitalisierung:
$2.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-10.69
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
+1.25%
1M Leistung:
-0.12%
6M Leistung:
+24.94%
1J Leistung:
+64.74%
1-Tages-Spanne:
$33.84
$34.85
1-Wochen-Bereich:
$33.01
$34.86
52-Wochen-Spanne:
$19.12
$36.60
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
33.97 | 2.39B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
PHVS|Pharvaris NV|Price:34.170|Chg%:+0.910 - TradingKey
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris NV (PHVS) Institutional Confidence - TradingKey
Pharvaris NV (PHVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Pharvaris Director Sells Shares Worth $1.33 Million - sekbernews.id
Pharvaris N.V. Revenue Breakdown – NASDAQ:PHVS - TradingView
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? - The Motley Fool
Pharvaris publishes review on bradykinin B2 receptor research - Investing.com
Pharvaris publishes review on bradykinin B2 receptor research By Investing.com - Investing.com Canada
Here's why Pharvaris NV (PHVS) is a great momentum stock to buy - MSN
(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Morgan Stanley Maintains Pharvaris N.V. (PHVS) Overweight Recommendation - MSN
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy - Yahoo Finance
PHVS Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pharvaris stock with Overweight rating - Investing.com
Wells Fargo initiates Pharvaris stock with Overweight rating By Investing.com - Investing.com Canada
Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event - Stock Titan
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade - Zacks Investment Research
Form 144 Pharvaris N.V. For: 13 July By Investing.com - Investing.com Nigeria
Pharvaris (PHVS) holder Berndt Modig files to sell 2,292 shares - Stock Titan
FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks - Contemporary Pediatrics
FDA accepts Pharvaris NDA for oral HAE attack treatment drug - Investing.com
FDA accepts Pharvaris NDA for oral HAE attack treatment drug By Investing.com - Investing.com Nigeria
Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan
PHVSPharvaris NV Latest SEC Filings - Finviz
Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing - marketscreener.com
Pharvaris Insider Sold Shares Worth $2,695,452, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan - Stock Titan
Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares - Stock Titan
Pharvaris (PHVS) Faces Resistance as Stock Slips 2.5%Time Weighted Price - dars.gov.et
PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026 - Stock Titan
PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026 - Stock Titan
Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS) - Stock Titan
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Form 144 Pharvaris N.V. For: 29 June By Investing.com - Investing.com South Africa
Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan
Pharvaris (PHVS) director’s 2,400-share Rule 10b5-1 stock sale detailed - Stock Titan
Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan - Stock Titan
PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares - Stock Titan
PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS) - Stock Titan
8,300-share option exercise; multiple 10b5-1 sales reported (PHVS) - Stock Titan
Price to book forward of Pharvaris N.V. – GETTEX:9EN - TradingView
Pharvaris (PHVS) Gains 2.13% as Shares Approach Key Resistance LevelDividend Stock Picks - dars.gov.et
Liquidity Mapping Around (PHVS) Price Events - Stock Traders Daily
PHVS Gains 2.13% as Biotech Sentiment Brightens – Key Levels to WatchValue Factor - dars.gov.et
Price to book forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):